Gain Therapeutics (NASDAQ:GANX) Stock Price Down 10.1%

Gain Therapeutics, Inc. (NASDAQ:GANX) shares were down 10.1% during trading on Monday . The company traded as low as $3.55 and last traded at $3.65. Approximately 209,466 shares changed hands during trading, an increase of 19% from the average daily volume of 175,444 shares. The stock had previously closed at $4.06.

Analysts Set New Price Targets

Several research firms have weighed in on GANX. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research note on Wednesday. HC Wainwright lowered their price objective on shares of Gain Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, December 4th.

Gain Therapeutics Trading Down 1.8 %

The company has a market cap of $48.15 million, a P/E ratio of -2.08 and a beta of 0.47. The stock’s 50-day moving average is $4.28 and its two-hundred day moving average is $3.44. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.30 and a quick ratio of 2.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Gain Therapeutics by 25.8% during the 4th quarter. Vanguard Group Inc. now owns 88,385 shares of the company’s stock valued at $289,000 after buying an additional 18,105 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Gain Therapeutics by 227.7% during the 4th quarter. Northern Trust Corp now owns 43,513 shares of the company’s stock valued at $142,000 after buying an additional 30,236 shares in the last quarter. Royal Bank of Canada lifted its stake in shares of Gain Therapeutics by 947.6% during the 3rd quarter. Royal Bank of Canada now owns 210,000 shares of the company’s stock valued at $689,000 after buying an additional 189,954 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Gain Therapeutics by 23.0% during the 2nd quarter. Renaissance Technologies LLC now owns 47,600 shares of the company’s stock valued at $213,000 after buying an additional 8,900 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Gain Therapeutics by 17.1% during the 2nd quarter. BlackRock Inc. now owns 29,024 shares of the company’s stock valued at $130,000 after buying an additional 4,246 shares in the last quarter. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.